Haemonetics Corp

Research Haemonetics Corp (HAE) on Bullrun: valuation model: 16.7% overvalued, market cap USD 3.41B, P/E 37.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHAE
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal16.7% overvalued
• Market capUSD 3.41B
• P/E37.0
• Financial periodFY2026
• RevenueUSD 1.33B
• Revenue growth-2.0%
• Net incomeUSD 97.31M
• Free cash flowUSD 260.44M
• Gross margin59.0%

Valuation Snapshot

Bullrun's latest valuation model marks Haemonetics Corp as 16.7% overvalued; latest market cap is USD 3.41B; P/E is 37.0.

About Haemonetics Corp

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain;

Frequently asked questions

Is Haemonetics Corp overvalued or undervalued?

Bullrun's valuation model currently marks Haemonetics Corp as 16.7% overvalued.

What is Haemonetics Corp's market cap?

Haemonetics Corp's market capitalization is USD 3.41B.

What is Haemonetics Corp's P/E ratio?

Haemonetics Corp's price-to-earnings (P/E) ratio is 37.0.

What does Haemonetics Corp do?

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.